Company intelligence / Profile preview

Petra Pharma

New York, New York, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Petra Pharma developed novel small molecule inhibitors targeting PI signaling for cancer and metabolic diseases; lead programs remained in discovery or preclinical stage at time of company acquisition in 2020.

Therapeutic areas: HematologyOncologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Weill Cornell MedicineDana-Farber Cancer Institute

Beyond the preview

Go deeper on Petra Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Petra Pharma.

Explore the full profile